NASDAQ:RNAC Cartesian Therapeutics 5/8/2025 Earnings Report $9.76 -0.24 (-2.40%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$9.78 +0.03 (+0.26%) As of 06/20/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Cartesian Therapeutics EPS ResultsActual EPS-$0.68Consensus EPS -$0.61Beat/MissMissed by -$0.07One Year Ago EPSN/ACartesian Therapeutics Revenue ResultsActual Revenue$1.10 millionExpected Revenue$0.69 millionBeat/MissBeat by +$412.00 thousandYoY Revenue GrowthN/ACartesian Therapeutics Announcement DetailsQuarterDate5/8/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsCartesian Therapeutics' next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules. Conference Call ResourcesSEC FilingEarnings HistoryCompany Profile Cartesian Therapeutics Earnings HeadlinesWe're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn RateJune 21 at 8:01 PM | finance.yahoo.comCartesian Therapeutics holds annual stockholders meetingJune 18, 2025 | investing.comWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… And it's all thanks to President Trump. His administration has begun to fast-track the operations of a handful of companies… Accelerating their potential profits.June 22, 2025 | InvestorPlace (Ad)Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $43.00 Consensus PT from AnalystsJune 17, 2025 | americanbankingnews.comCartesian Therapeutics Announces New Employment Inducement GrantsJune 3, 2025 | globenewswire.comBTIG Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)June 2, 2025 | theglobeandmail.comSee More Cartesian Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cartesian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cartesian Therapeutics and other key companies, straight to your email. Email Address About Cartesian TherapeuticsCartesian Therapeutics (NASDAQ:RNAC), a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.View Cartesian Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Upcoming Earnings FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)Wells Fargo & Company (7/14/2025)JPMorgan Chase & Co. (7/14/2025)Interactive Brokers Group (7/15/2025)America Movil (7/15/2025)Citigroup (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
